Journal article 805 views
P2Y12 receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: use, patient selection, and outcomes from contemporary European registries
,
Azfar Zaman,
Pontus Andell,
Jin Li,
J. Wouter Jukema
European Heart Journal - Cardiovascular Pharmacotherapy, Volume: 2, Issue: 4, Pages: 229 - 243
Swansea University Author:
Clive Weston
Full text not available from this repository: check for access using links below.
DOI (Published version): 10.1093/ehjcvp/pvw005
Abstract
Non-ST-elevation acute coronary syndrome (NSTE-ACS) is present in about 60–70% of patients admitted with ACS. This study provides a ‘real-life’ overview of NSTE-ACS patient characteristics, dual antiplatelet therapy, and outcomes at both the time of discharge from hospital and up to 1-year post-disc...
| Published in: | European Heart Journal - Cardiovascular Pharmacotherapy |
|---|---|
| ISSN: | 2055-6837 2055-6845 |
| Published: |
2016
|
| Online Access: |
Check full text
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa31533 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract: |
Non-ST-elevation acute coronary syndrome (NSTE-ACS) is present in about 60–70% of patients admitted with ACS. This study provides a ‘real-life’ overview of NSTE-ACS patient characteristics, dual antiplatelet therapy, and outcomes at both the time of discharge from hospital and up to 1-year post-discharge.10 registries (including 84 054 NSTE-ACS patients) provided data on patient characteristics and outcomes, and 6 of these (with 52 173 NSTE-ACS patients) also provided more specific data according to P2Y12 receptor inhibitor used. Unadjusted analyses were performed at the study level, and no formal meta-analysis was performed due to large heterogeneity between studies in the settings, patient characteristics, and outcome definitions. All-cause death rates across registries ranged from 0.76 to 4.79% in-hospital, from 1.61 to 6.65% at 30 days, from 3.66 to 7.16% at 180 days, and from 3.14 to 9.73% at 1 year. Major bleeding events were reported in up to 2.77% of patients while in hospital (in seven registries), up to 1.08% at 30 days (data from one registry only), and 2.06% at 1 year (one registry).Conclusions There were substantial differences in the use of and patient selection for clopidogrel, prasugrel, and ticagrelor, which were associated with differences in short- and long-term ischaemic and bleeding events. |
|---|---|
| Keywords: |
Acute coronary syndrome, myocardial infarction, anti-platelet, registry |
| College: |
Faculty of Medicine, Health and Life Sciences |
| Issue: |
4 |
| Start Page: |
229 |
| End Page: |
243 |